Changes to the use of medicines containing the antibiotic azithromycin Authors: Robin Ruepp, Radu Botgros, Veronique Le Ber, Franziska Brandt, Ellen Pantke, Miriam Fuerst-Wilmes, Antonio Gomez-Outes, Maria Jesus Fernandez-Cortizo Published: 2025 Azithromycin is a macrolide antibiotic active against many aerobic Gram-positive and Gram-negative bacteria, including intracellular pathogens such as Chlamydia trachomatis. Oral solid, oral liquid and intravenous azithromycin formulations have been authorised for decades in the European Union (EU) in a wide range of infections commonly seen in the community, such as infections of the respiratory tract, the skin, the urogenital tract, and others. Azithromycin is part of the WHO Model List of Essential Medicines. In view of the observed level of antimicrobial resistance and its broad use, it is classified into the ‘Watch’ category of WHO’s AWaRe classification system, which categorises antibiotics into three groups—‘Access’, ‘Watch’ and ‘Reserve’—to promote responsible antibiotic use and curb antimicrobial resistance.1 Antibiotics categorised into the ‘Watch’ group have a higher potential for the selection of antimicrobial resistance. They should thus be part of antimicrobial stewardship programmes and be carefully monitored to avoid overuse. Nonetheless, in conflict with the principles of the rational use of antibiotics and antibiotic stewardship, azithromycin-containing medicines are frequently prescribed in the EU for adult and paediatric patients2 leading to increased resistance rates in relevant pathogens, including Neisseria gonorrhoeae.3 Since many azithromycin-containing medicines were authorised decades ago via national procedures per EU/EEA Member State, their Summary of Product Characteristics (SmPC) varies significantly between countries, and the wording of the approved indications needs to be brought in line with the current European Medicines Agency (EMA) guideline recommendations on the evaluation of medicinal products indicated for treatment of bacterial infections.4 Germany’s national competent authority, BfArM, triggered an EU/European Economic Area (EEA)-wide review,5 asking EMA’s Committee for medicinal products for human use (CHMP) to re-evaluate the benefit-risk balance of azithromycin-containing products for systemic use in all their indicated uses and to provide a harmonised position across Member States on behalf of the EU. The CHMP, supported by the Infectious Disease Working Party (IDWP) and the Pharmacovigilance Risk Assessment Committee (PRAC), critically reviewed all available data from clinical, pharmacokinetic/pharmacodynamic and epidemiological studies, scientific literature, post-marketing evidence reports of resistance development against relevant pathogens, pharmacovigilance data, a risk assessment on the probability of development of resistance during treatment, and recommendations in current national and European treatment guidelines. Based on CHMP’s evaluation, the European Commission (EC) has now issued a decision to be applied in all EU and EEA Member States.6 The data assessed indicates that safety concerns for azithromycin are minimal and no threshold could reasonably be established for a mean level of resistance above which a first-line indication would no longer be appropriate. Consequently, a restriction to second-line use only was not considered appropriate, particularly taking into account that a recommendation should be included in the indications section 4.1 of the SmPC of all antibacterial agents that “consideration should be given to official guidance on the appropriate use of antibacterial agents”.4 The product information of medicines containing azithromycin has emphasised for many years that official guidance on the appropriate use of antibacterial agents should be considered.3, Use data nonetheless indicate that these medicines may be prescribed too broadly and too often,2 7 while recent European Centre for Disease Prevention and Control (ECDC) data also show an increasing level of resistance8 and use9 over time. As an outcome of the review, the product information for all azithromycin-containing medicines has therefore been updated with a warning about the potential for resistance development reading as follows: “azithromycin could favour the development of resistance due to the associated long-lasting and decreasing levels in plasma and tissues after the end of treatment ” and “treatment with azithromycin should only be initiated after a careful assessment of the benefit and the risks, considering the local prevalence of resistance, and when preferred treatment regimens are not indicated”. However, the benefit-risk balance was no longer considered favourabe for the indications ‘treatment of (moderate) acne vulgaris’, ‘treatment of gastro-duodenal infections caused by Helicobacter pylori’ (in the context of evolving treatment standards and the concern over selection for resistance with long-term treatment) and ‘prevention of exacerbations of eosinophilic and non-eosinophilic asthma’ (due to recent data casting serious doubts on the efficacy in this indication) . Consequently, these indications have been removed from the product information and medicines containing azithromycin should no longer be used for these conditions. Contraindications, posology, method of administration, interactions, and information on pregnancy, lactation and fertility have been harmonised and refined for clarity and for alignment with available evidence and currently accepted medical terminology. Dosing recommendations for paediatric patients (in particular for the oral liquid formulations) were also improved. Details of the changes to the product information in all EU/EEA languages are published as ‘Annex III’ of the Commission Decision on EMA’s website.5 Overall, based on the review of the available clinical data, the CHMP considered that the benefit-risk balance of azithromycin-containing medicines for systemic use remained favourable in the remaining indications (an overview is presented in box 1), subject to the amendments to the product information referred above . Most of these indications have been reworded to better specify the patient populations, for example, from the more general ‘Infections of the lower respiratory tract including acute bronchitis, chronic bronchitis, acute exacerbation of chronic bronchitis, pneumonia and atypical pneumonia’ in some European Member States to ‘Acute exacerbations of chronic bronchitis’ and ‘Community-acquired pneumonia’), and to follow the current clinical terminology, for example, from ‘Skin and soft tissue infections (folliculitis, cellulitis,…)’ to ‘Acute bacterial skin and skin structure infections’. Details of CHMP’s assessment are available in the European Public Assessment Report.5 Changes to the therapeutic indications section 4.1 of the summary of product characteristics of systemic azithromycin-containing medicines Indications maintained/reworded to: Treatment of: Acute streptococcal tonsillitis and pharyngitis. Acute streptococcal tonsillitis and pharyngitis. Acute bacterial sinusitis. Acute bacterial sinusitis. Acute bacterial otitis media. Acute bacterial otitis media. Acute exacerbations of chronic bronchitis (adult patients only). Acute exacerbations of chronic bronchitis (adult patients only). Community-acquired pneumonia. Community-acquired pneumonia. Acute bacterial skin and skin structure infections. Acute bacterial skin and skin structure infections. Erythema migrans (early localised Lyme disease). Erythema migrans (early localised Lyme disease). Periodontal abscesses and periodontitis. Periodontal abscesses and periodontitis. Chronic prostatitis caused by Chlamydia trachomatis. Chronic prostatitis caused by Chlamydia trachomatis. Urethritis and cervicitis caused by C. trachomatis. Urethritis and cervicitis caused by C. trachomatis. Urethritis and cervicitis caused by Neisseria gonorrhoeae, in combination with another appropriate antibacterial agent (eg, ceftriaxone). Urethritis and cervicitis caused by Neisseria gonorrhoeae, in combination with another appropriate antibacterial agent (eg, ceftriaxone). Chancroid. Chancroid. Pelvic inflammatory disease, in combination with other appropriate antibacterial agent(s) (eg, metronidazole) (adult women only). Pelvic inflammatory disease, in combination with other appropriate antibacterial agent(s) (eg, metronidazole) (adult women only). Disseminated Mycobacterium avium complex infection in people living with advanced HIV infection, in combination with ethambutol. Disseminated Mycobacterium avium complex infection in people living with advanced HIV infection, in combination with ethambutol. Prophylaxis of M. avium complex infection in people living with HIV with inadequate immune restoration. Indications deleted Treatment of: (Moderate) acne vulgaris. (Moderate) acne vulgaris. Gastro-duodenal infections caused by Helicobacter pylori. Gastro-duodenal infections caused by Helicobacter pylori. Prevention of exacerbations of eosinophilic and non-eosinophilic asthma. Note that this table does not reflect other changes to the product information, such as posology and method of administration, which may affect patient treatment. Discussion The changes to the indications and the clearer posology recommendations, in combination with the warnings regarding resistance, aim to give clearer instructions to healthcare professionals which patients would benefit most from these medicines, such as patients, such as those with hypersensitivity to beta-lactam agents, or paediatric patients with suspected or confirmed community-acquired pneumonia due to pathogens such as Mycoplasma pneumoniae for which treatment alternatives are limited. A more focused prescription using adequate dosing should reduce the chance of pathogens acquiring further azithromycin resistance, so that these medicines can remain an important part in the armamentarium against those infections that are very prevalent in the community and for which treatment alternatives may be limited. However, the changes to the product information will also need to be accompanied by a multipronged approach covering harmonised changes to clinical guidance across Europe and antibiotic stewardship programmes to raise awareness for prescribers. To monitor the success of this approach, further drug utilisation studies and observational studies that monitor resistance patterns will be necessary. Conclusions As a result of this CHMP review, although azithromycin-containing medicines have a relatively favourable safety profile and allow for short-term courses of treatment, healthcare professionals are nonetheless urged to prescribe other antibiotics that are less prone to resistance development, even when posology of such alternatives is less convenient. It is expected that the changes to the indications, posology and added warnings will inform healthcare professionals to change prescribing practices, moving from treatment of a broad range of relatively uncomplicated infections to a more targeted use restricted to the patients who would benefit most from treatment. These updates to the product information will, however, need to be accompanied with communication activities through antibiotic stewardship programmes and updates to EU/EEA guidelines. Studies will need to be in place to measure their success. Acknowledgements The authors are grateful to Jarno Janssen, Thomas Larsson and Justine Pourchasse for their review and constructive comments on the manuscript. The views expressed in this article are the personal views of the authors and may not be understood or quoted as being made on behalf of or reflecting the position of the regulatory agencies or organisations with which the authors are affiliated. Footnotes Funding: The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors. Patient consent for publication: Not applicable. Ethics approval: Not applicable. Provenance and peer review: Not commissioned; externally peer reviewed. Patient and public involvement: Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research. Data availability statement All data relevant to the study are included in the article. References Associated Data Data Availability Statement All data relevant to the study are included in the article.